The news: Eli Lilly’s GLP-1 medication, tirzepatide (marketed as Zepbound and Mounjaro), is no longer in shortage in the US, according to the FDA.
- The regulator confirmed with Lilly that its stated product availability and manufacturing capacity can meet the current and projected national demand.
Yes, and: The FDA clarified its policies for pharmacies making compounded versions of brand-name drugs, including GLP-1s, which has become an en vogue practice amidst a broader shortage of the meds.
Compounded drugs aren’t approved by the FDA and must meet conditions to qualify for exemptions under sections 503A and 503B of the Federal Food, Drug and Cosmetic Act.